Pitavastatin, a cholesterol lowering drug, slashes chemotherapy resistance in breast cancer by obstructing a specific protein ...

Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and ...

Lipid imbalance triggered by Snail-driven epithelial–mesenchymal transition creates a cholesterol-dependent vulnerability ...

A shift in the balance between two lipids – cholesterol and sphingomyelin – makes hybrid epithelial-mesenchymal cancer cells less responsive to certain chemotherapy drugs.

Small cell lung cancer, or SCLC, is aggressive, lethal and particularly cruel because chemotherapy initially works so well. But within just a few months, SCLC becomes resistant to drugs and dashes ...

WILMINGTON, DEL. (November 14, 2025) – In a major step forward for cancer care, researchers at ChristianaCare’s Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology ...

Cancer Research UK-funded scientists at the University of Cambridge, in collaboration with the Spanish National Cancer Research Centre (CNIO) and Cambridge-based startup Tailor Bio, have created a ...

Researchers have identified chromosomal instability in circulating tumour cells as a prognostic and predictive biomarker in ...

A Korea University research team has discovered that pitavastatin, a widely used lipid-lowering drug, can directly inhibit ...